ATHA - getting ready for a recovery if breaks above 22.5

NASDAQ:ATHA   Athira Pharma, Inc.
Fundamentals: ATHA is a biotech company whose primary product is focuses on Alzheimer's disease. This is product, if approved, promises to be in a very high demand. Recently company issued additional shares, which send the stock plummeting.

Technicals: ATHA might be working out on a 2nd wave. If this hypothesis proves true, the next 3rd wave can get the stock to at least 40s.


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.